Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Positive Free Cash Flow ⢠Rising Debt Load ⢠Thin Net Margins RDNT's improving EBITDA and free cash flow are encouraging, but rising leverage, thin net margins, and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Key support holds ⢠Resistance caps gains ⢠Balanced momentum Support Level: $75.50â$75.80 Resistance Level: $77.00â$77.80 RDNT is cautiously bullish above $75.50 and its last-month average, but needs a sustained break above $77.80 to confirm upside momentum.
Sentiment & News
Key News Insights: ⢠Bamco Stake ⢠Investor Conferences ⢠Patient Outreach RadNet gained investor visibility through major institutional buying, conference participation, and patient outreach, supporting its growth profile.
AI Summary
RadNet's investment case has shifted to a two-engine modelâcash-generative imaging plus DeepHealth AIâbut at ~25x EBITDA, investors should wait for Digital Health ARR growth and core EBITDA gains to translate into durable margin and EPS expansion, as leverage and ~1% net margins leave little room for execution misses.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 10 | Aug 17 | RDNT | RadNet, Inc. | Healthcare diagnostics momentum backed by Q2 record revenue of $622.7M, adjusted EBITDA of $99.7M, ARR up to $105.5M from $53.5M YoY, raised 2026 Imaging Center guidance, reaffirmed Digital Health guidance, and multiple FDA 510(k) clearances. | Closed | -1.8% |
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |